1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Ramelteon: A Melatonin Receptor Agonist in the Treatment of Insomnia (2006)

Ramelteon: A Melatonin Receptor Agonist in the Treatment of Insomnia (2006)

  1. Jatelka
    European Neurological Review, 2006;6(1):1-7
    DOI: 10.17925/ENR.2006.00.01.1f

    Levian, Terri
    Review article. Provides an overview of Pharmacology, Pharmacokinetics, Efficacy (trial data) and Cautions/Interactions.

    Abstract
    Ramelteon is the first FDA-approved melatonin receptor agonist. Ramelteon reduces the time-to- sleep onset and increases total sleep duration; however, comparative studies with other sleep agents, including melatonin, are necessary to determine comparative efficacy and the place of ramelteon in therapy. Efficacy in placebo-controlled study has been observed in both acute and chronic insomnia.
    Similar to eszopiclone, long-term studies have been conducted and recommended use is not limited to 30 days. Ramelteon was well tolerated in clinical studies, with little residual sedation, and has not been associated with physical dependence or abuse liability.